ArticleFrontiers in nutrition2025
Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Peripheral nerve complications from medications utilised for weight loss: a systematic review.Journal of neurology · 2026Pooled it
- Vitamins and Chronic Wounds: How Altered Pharmacokinetics and Comorbidities Contribute to Vitamin Deficiencies.Basic & clinical pharmacology & toxicology · 2026Review
- Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol.Obesity science & practice · 2026Article
- Article
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Medical sciences (Basel, Switzerland) · 2026Review
- Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.International journal of molecular sciences · 2026Review
- Obesity and Iron Metabolism: Mechanisms, Status Assessment, and Clinical Implications.Current obesity reports · 2026Review
- Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.Obesity pillars · 2026Article
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.Obesity pillars · 2026Review
- Review
- GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review.Cancers · 2026Review
- Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care.Nutrients · 2026Review
- Review
- Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care.The Journal of nutrition · 2026Article
- Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy.Journal of clinical medicine · 2026Review
- Perioperative Nutrition and Surgical Outcomes in Patients Receiving Glucagon-like Peptide-1 Receptor Agonists: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
- Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy.Current developments in nutrition · 2026Article
- Review
- GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity.Current nutrition reports · 2026Article
- GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrient intake while using a GLP-1RA. The purpose of this study was to compare nutrient intake while using a GLP-1RA to the Dietary Reference Intakes (DRI). Methods: A cross-sectional study was conducted in a sample of participants who had been using GLP-1RA for at least one month ( Results: Compared to the DRI reference values, participants consumed adequate amounts of B-vitamins, copper, phosphorus, selenium, and zinc. Participants had insufficient intakes of several key nutrients below the DRI, including fiber (14.5 g; CI: 12-17), calcium (863 mg; CI: 756-970), iron (12.1 mg; CI: 11-13), magnesium (266 mg; CI: 236-297), potassium (2,186 mg; CI: 1,969-2,402), choline (305 mg; CI: 268-342), vitamin A (560 mcg RAE; CI: 469-651), vitamin C (51 mg; CI: 41-61), vitamin D (4 mcg; CI: 3-5), vitamin E (9.6 mg; CI: 8-11), and Conclusion: Participants on a GLP-1RA are not meeting the DRI for several vital nutrients through their diet or higher protein needs during weight loss. Patient-centered nutritional guidance is essential to optimize health outcomes and prevent unintended health consequences. Future large-scale studies are needed to assess the replicability of these findings and provide custom nutritional guidance for those on a GLP-1RA medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.